Showing results (71-80 of 156) with videos related to

Sort By:
Pageof 16
Frontiers in Immunology|March 21, 2020
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor TherapyIoana Plesca, Antje Tunger, Luise Müller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profilesOlga Modlich, Hans-Bernd Prisack, Gerald Pitschke, et al.
Molecular Endocrinology (Baltimore, Md.)|September 10, 2014
A natural androgen receptor antagonist induces cellular senescence in prostate cancer cellsWiebke Hessenkemper, Julia Roediger, Sophie Bartsch, et al.
Biomedicines|September 23, 2022
Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early SalvageDaniel Wegener, Daniel M Aebersold, Marc-Oliver Grimm, et al.
Cancer Investigation|January 8, 2011
Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinomaMarieta I Toma, Thomas Weber, Matthias Meinhardt, et al.
Anticancer Research|August 30, 2008
Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cellsDoreen Kunze, Daniela Wuttig, Susanne Fuessel, et al.
The Oncologist|November 11, 2023
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell CarcinomaRana R McKay, Katharina Leucht, Wanling Xie, et al.
Journal of Medical Economics|April 19, 2024
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims dataGünter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, et al.
European Urology|June 21, 2025
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS TrialMarc-Oliver Grimm, Matthew Smith, Maha Hussain, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2026
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancerAlicia K Morgans, Christopher J D Wallis, Susan Halabi, et al.
Pageof 16